$HLYK
HealthLynked Corp

2024 Q4 Form 10-Q Financial Statement

#000121390024098383 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $590.1K
YoY Change -55.71%
Cost Of Revenue $381.1K
YoY Change -33.12%
Gross Profit $209.0K
YoY Change -72.6%
Gross Profit Margin 35.41%
Selling, General & Admin $631.8K
YoY Change -17.7%
% of Gross Profit 302.34%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $27.67K
YoY Change -8.85%
% of Gross Profit 13.24%
Operating Expenses $2.261M
YoY Change 194.58%
Operating Profit -$1.671M
YoY Change 41.06%
Interest Expense -$304.4K
YoY Change -132.7%
% of Operating Profit
Other Income/Expense, Net -$301.8K
YoY Change -129.49%
Pretax Income -$1.973M
YoY Change 1122.73%
Income Tax
% Of Pretax Income
Net Earnings -$1.973M
YoY Change 1027.99%
Net Earnings / Revenue -334.36%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$0.01
COMMON SHARES
Basic Shares Outstanding 281.9M shares 281.9M shares
Diluted Shares Outstanding 281.9M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.96K
YoY Change -70.86%
Cash & Equivalents $14.96K
Short-Term Investments
Other Short-Term Assets $92.03K
YoY Change -98.38%
Inventory $78.82K
Prepaid Expenses
Receivables $25.56K
Other Receivables $1.663M
Total Short-Term Assets $1.824M
YoY Change -17.15%
LONG-TERM ASSETS
Property, Plant & Equipment $205.0K
YoY Change -36.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $50.05K
YoY Change -97.07%
Total Long-Term Assets $933.7K
YoY Change -73.23%
TOTAL ASSETS
Total Short-Term Assets $1.824M
Total Long-Term Assets $933.7K
Total Assets $2.758M
YoY Change -51.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $705.0K
YoY Change -56.57%
Accrued Expenses $57.41K
YoY Change -56.41%
Deferred Revenue $212.8K
YoY Change 7.6%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $199.1K
YoY Change -44.21%
Total Short-Term Liabilities $3.807M
YoY Change 13.28%
LONG-TERM LIABILITIES
Long-Term Debt $533.5K
YoY Change 12.92%
Other Long-Term Liabilities $351.0K
YoY Change 18.76%
Total Long-Term Liabilities $884.5K
YoY Change 15.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.807M
Total Long-Term Liabilities $884.5K
Total Liabilities $4.691M
YoY Change 13.63%
SHAREHOLDERS EQUITY
Retained Earnings -$46.93M
YoY Change 15.18%
Common Stock $28.20K
YoY Change 6.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.933M
YoY Change
Total Liabilities & Shareholders Equity $2.758M
YoY Change -51.52%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.973M
YoY Change 1027.99%
Depreciation, Depletion And Amortization $27.67K
YoY Change -8.85%
Cash From Operating Activities -$1.037M
YoY Change -17.21%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 879.2K
YoY Change 3872.98%
NET CHANGE
Cash From Operating Activities -1.037M
Cash From Investing Activities 0.000
Cash From Financing Activities 879.2K
Net Change In Cash -157.8K
YoY Change -81.88%
FREE CASH FLOW
Cash From Operating Activities -$1.037M
Capital Expenditures $0.00
Free Cash Flow -$1.037M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
usd
dei Document Type
DocumentType
10-Q
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55768
dei Entity Registrant Name
EntityRegistrantName
HealthLynked Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1634127
dei Entity Address Address Line1
EntityAddressAddressLine1
1265 Creekside Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 302
dei Entity Address City Or Town
EntityAddressCityOrTown
Naples
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34108
dei City Area Code
CityAreaCode
(800)
dei Local Phone Number
LocalPhoneNumber
928-7144
dei Security12b Title
Security12bTitle
None
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
281947151 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14958 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247222 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25557 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20861 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
78819 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
133222 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
41980 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
55210 usd
CY2024Q3 hlyk Contingent Sale Consideration Receivable Current Portion
ContingentSaleConsiderationReceivableCurrentPortion
1663163 usd
CY2023Q4 hlyk Contingent Sale Consideration Receivable Current Portion
ContingentSaleConsiderationReceivableCurrentPortion
199645 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1824477 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
656160 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
606403 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
521062 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
205012 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
290755 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
0 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
258690 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
883848 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
678622 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
935812 usd
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
50047 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
50047 usd
CY2023Q4 hlyk Contingent Sale Consideration Receivable Long Term Portion
ContingentSaleConsiderationReceivableLongTermPortion
1463518 usd
CY2024Q3 us-gaap Assets
Assets
2758158 usd
CY2023Q4 us-gaap Assets
Assets
4280140 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
704953 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
614178 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
212793 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
271774 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
329322 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
326033 usd
CY2024Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
45557 usd
CY2023Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
166487 usd
CY2024Q3 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
199141 usd
CY2023Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
584323 usd
CY2024Q3 hlyk Indemnification Liability
IndemnificationLiability
143974 usd
CY2023Q4 hlyk Indemnification Liability
IndemnificationLiability
143974 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3806590 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2412024 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
350951 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
613386 usd
CY2024Q3 hlyk Government And Vendor Notes Payable Long Term Portion
GovernmentAndVendorNotesPayableLongTermPortion
533536 usd
CY2023Q4 hlyk Government And Vendor Notes Payable Long Term Portion
GovernmentAndVendorNotesPayableLongTermPortion
450000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
4691077 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3475410 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
281947151 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
281947151 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
275964958 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
275964958 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
28195 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
27597 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
2750 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
2750 usd
CY2024Q3 hlyk Common Stock Issuable Par Value
CommonStockIssuableParValue
0.0001
CY2023Q4 hlyk Common Stock Issuable Par Value
CommonStockIssuableParValue
0.0001
CY2024Q3 hlyk Common Stock Issuable Shares
CommonStockIssuableShares
2649203 shares
CY2023Q4 hlyk Common Stock Issuable Shares
CommonStockIssuableShares
2764352 shares
CY2024Q3 hlyk Common Stock Issuable Value
CommonStockIssuableValue
147509 usd
CY2023Q4 hlyk Common Stock Issuable Value
CommonStockIssuableValue
281682 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44823036 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42525837 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46934409 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42033136 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1932919 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
804730 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2758158 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4280140 usd
CY2024Q3 us-gaap Revenues
Revenues
590124 usd
CY2023Q3 us-gaap Revenues
Revenues
1332515 usd
us-gaap Revenues
Revenues
2389434 usd
us-gaap Revenues
Revenues
4791165 usd
CY2024Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
449759 usd
CY2023Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
772416 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
1546806 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
2635065 usd
CY2024Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
349467 usd
CY2023Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
529067 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1221272 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1799530 usd
CY2024Q3 hlyk Cost Of Product Revenue
CostOfProductRevenue
31674 usd
CY2023Q3 hlyk Cost Of Product Revenue
CostOfProductRevenue
40820 usd
hlyk Cost Of Product Revenue
CostOfProductRevenue
86976 usd
hlyk Cost Of Product Revenue
CostOfProductRevenue
107277 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
631828 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
767705 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2492740 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2705142 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
82743 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
87392 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
254514 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
263762 usd
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
716000 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
319958 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
716000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
319958 usd
CY2024Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2261471 usd
CY2023Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2517358 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
6318308 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
7830734 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1671347 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1184843 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3928874 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3039569 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2580 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-167647 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-88932 usd
CY2024Q3 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
65344 usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
93244 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
92641 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
92641 usd
CY2024Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
322141 usd
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
132155 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
801762 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
324204 usd
CY2023Q3 hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
1075857 usd
hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
1090857 usd
CY2024Q3 hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
1478 usd
CY2023Q3 hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
4819 usd
hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
2189 usd
hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
9183 usd
CY2024Q3 us-gaap Interest Expense Other
InterestExpenseOther
49033 usd
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
17689 usd
us-gaap Interest Expense Other
InterestExpenseOther
98423 usd
us-gaap Interest Expense Other
InterestExpenseOther
68194 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-301772 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1023473 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-972399 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
711351 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1973119 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-161370 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4901273 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2328218 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1973119 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-161370 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-4901273 usd
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2328218 usd
CY2023Q3 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
-13554 usd
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
-72295 usd
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
-2674069 usd
CY2023Q3 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
-13554 usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
2601774 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1973119 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-174924 usd
us-gaap Net Income Loss
NetIncomeLoss
-4901273 usd
us-gaap Net Income Loss
NetIncomeLoss
273556 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.02
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.01
CY2024Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.02
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
CY2024Q3 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicShare
0
CY2023Q3 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicShare
0
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicShare
0
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerBasicShare
0.01
CY2024Q3 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerDilutedShare
0
CY2023Q3 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerDilutedShare
0
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerDilutedShare
0
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTaxPerDilutedShare
0.01
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
281947151 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
265519460 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
281428579 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
260853370 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
281947151 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
265519460 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
281428579 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
260853370 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
804730 usd
CY2024Q1 hlyk Stock Issued During Period Sales Of Common Stock Persuant Standly By Equity Purchase Agreement
StockIssuedDuringPeriodSalesOfCommonStockPersuantStandlyByEquityPurchaseAgreement
255923 usd
CY2024Q1 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Common Stock
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfCommonStock
99077 usd
CY2024Q1 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt
209943 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
146405 usd
CY2024Q1 hlyk Adjustmentto Additional Paidin Capital Consultant And Director Fees Payable With Common Shares And Warrants
AdjustmenttoAdditionalPaidinCapitalConsultantAndDirectorFeesPayableWithCommonSharesAndWarrants
43437 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
49697 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1387718 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
221494 usd
CY2024Q2 hlyk Stock Issued During Period Sales Of Common Stock Persuant Standly By Equity Purchase Agreement
StockIssuedDuringPeriodSalesOfCommonStockPersuantStandlyByEquityPurchaseAgreement
38821 usd
CY2024Q2 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Common Stock
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfCommonStock
11178 usd
CY2024Q2 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt
364422 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
392905 usd
CY2024Q2 hlyk Adjustmentto Additional Paidin Capital Consultant And Director Fees Payable With Common Shares And Warrants
AdjustmenttoAdditionalPaidinCapitalConsultantAndDirectorFeesPayableWithCommonSharesAndWarrants
69624 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
17413 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1540436 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-424579 usd
CY2024Q3 hlyk Stock Issued During Period Sales Of Common Stock Persuant Standly By Equity Purchase Agreement
StockIssuedDuringPeriodSalesOfCommonStockPersuantStandlyByEquityPurchaseAgreement
-29134 usd
CY2024Q3 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt
209931 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
242979 usd
CY2024Q3 hlyk Adjustmentto Additional Paidin Capital Consultant And Director Fees Payable With Common Shares And Warrants
AdjustmenttoAdditionalPaidinCapitalConsultantAndDirectorFeesPayableWithCommonSharesAndWarrants
33635 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
7368 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1973119 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1932919 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
314450 usd
CY2023Q1 hlyk Stock Issued During Period Sales Of Common Stock Persuant Standly By Equity Purchase Agreement
StockIssuedDuringPeriodSalesOfCommonStockPersuantStandlyByEquityPurchaseAgreement
18765 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
126198 usd
CY2023Q1 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Common Stock
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfCommonStock
73802 usd
CY2023Q1 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt
95393 usd
CY2023Q1 hlyk Adjustmentto Additional Paidin Capital Consultant And Director Fees Payable With Common Shares And Warrants
AdjustmenttoAdditionalPaidinCapitalConsultantAndDirectorFeesPayableWithCommonSharesAndWarrants
54972 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
33128 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
1451935 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2168643 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
154614 usd
CY2023Q2 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Common Stock
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfCommonStock
120386 usd
CY2023Q2 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt
50025 usd
CY2023Q2 hlyk Adjustmentto Additional Paidin Capital Consultant And Director Fees Payable With Common Shares And Warrants
AdjustmenttoAdditionalPaidinCapitalConsultantAndDirectorFeesPayableWithCommonSharesAndWarrants
52636 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
24613 usd
CY2023Q2 hlyk Adjustments To Additional Paid In Capital Incremental Fair Value Of Repriced Warrants
AdjustmentsToAdditionalPaidInCapitalIncrementalFairValueOfRepricedWarrants
4358 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1003455 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1571820 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
48880 usd
CY2023Q3 hlyk Adjustmentto Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Related Party Debt
AdjustmenttoAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfRelatedPartyDebt
44212 usd
CY2023Q3 hlyk Adjustments To Additional Paid In Capital Fair Value Of Warrants Allocated To Proceeds Of Third Party Debt
AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsAllocatedToProceedsOfThirdPartyDebt
15140 usd
CY2023Q3 hlyk Adjustmentto Additional Paidin Capital Consultant And Director Fees Payable With Common Shares And Warrants
AdjustmenttoAdditionalPaidinCapitalConsultantAndDirectorFeesPayableWithCommonSharesAndWarrants
38345 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
17420 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-174924 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1560893 usd
us-gaap Net Income Loss
NetIncomeLoss
-4901273 usd
us-gaap Net Income Loss
NetIncomeLoss
273556 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-72295 usd
hlyk Gain From Disposal Of Discontinued Operations
GainFromDisposalOfDiscontinuedOperations
2674069 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
254514 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
263762 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1675 usd
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
1148 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
716000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
319958 usd
us-gaap Share Based Compensation
ShareBasedCompensation
192039 usd
us-gaap Share Based Compensation
ShareBasedCompensation
225472 usd
hlyk Gain From Expiration Of Liability Classified Equity Instruments
GainFromExpirationOfLiabilityClassifiedEquityInstruments
92641 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
801762 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
324204 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-167647 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-88932 usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
93244 usd
hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
1090857 usd
hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
2189 usd
hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
9183 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4696 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8252 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-54403 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-50580 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-13230 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-255710 usd
hlyk Increase Decrease In Right Of Use Lease Assets
IncreaseDecreaseInRightOfUseLeaseAssets
248913 usd
hlyk Increase Decrease In Right Of Use Lease Assets
IncreaseDecreaseInRightOfUseLeaseAssets
551736 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
110549 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-507408 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-249721 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-550848 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-58981 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-377079 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2750520 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2867628 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-84946 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2750520 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2952574 usd
hlyk Proceeds From Sale Of Discontinued Operations
ProceedsFromSaleOfDiscontinuedOperations
2321381 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2598 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1500 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2598 usd
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2319881 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2598 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2319881 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
405000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
475000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2675000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1048500 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
335000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
685250 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
67601 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
867400 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
826545 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
719220 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2520854 usd
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
622130 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2520854 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
622130 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-232264 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10563 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247222 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61891 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14958 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51328 usd
us-gaap Interest Paid Net
InterestPaidNet
19737 usd
us-gaap Interest Paid Net
InterestPaidNet
21041 usd
hlyk Recognition Of Operating Lease Right Of Use Asset And Lease Liability
RecognitionOfOperatingLeaseRightOfUseAssetAndLeaseLiability
28044 usd
hlyk Recognition Of Operating Lease Right Of Use Asset And Lease Liability
RecognitionOfOperatingLeaseRightOfUseAssetAndLeaseLiability
296004 usd
hlyk Extinguishment Of Operating Lease Right Of Use Asset And Lease Liability
ExtinguishmentOfOperatingLeaseRightOfUseAssetAndLeaseLiability
-37469 usd
hlyk Common Stock To Be Issued Now Issued
CommonStockToBeIssuedNowIssued
34105 usd
hlyk Fair Value Of Options Issued In Satisfaction Of Common Stock Issuable
FairValueOfOptionsIssuedInSatisfactionOfCommonStockIssuable
283869 usd
hlyk Fair Value Of Warrants Allocated To Proceeds Of Notes Payable
FairValueOfWarrantsAllocatedToProceedsOfNotesPayable
751158 usd
hlyk Fair Value Of Warrants Allocated To Proceeds Of Notes Payable
FairValueOfWarrantsAllocatedToProceedsOfNotesPayable
95393 usd
hlyk Fair Value Of Warrants Allocated To Proceeds Of Third Party Notes Payable
FairValueOfWarrantsAllocatedToProceedsOfThirdPartyNotesPayable
59351 usd
hlyk Fair Value Of Beneficial Conversion Feature Allocated To Proceeds Of Related Party Notes Payable
FairValueOfBeneficialConversionFeatureAllocatedToProceedsOfRelatedPartyNotesPayable
782292 usd
hlyk Fair Value Of Warrants Issued To Extend Debt
FairValueOfWarrantsIssuedToExtendDebt
33138 usd
hlyk Fair Value Of Warrants Issued To Extend Debt
FairValueOfWarrantsIssuedToExtendDebt
50025 usd
hlyk Incremental Fair Value Of Convertible Note Payable To Related Party Resulting From Refinancing
IncrementalFairValueOfConvertibleNotePayableToRelatedPartyResultingFromRefinancing
49680 usd
hlyk Note Payable To Related Party Balance Classified As Accrued Interest
NotePayableToRelatedPartyBalanceClassifiedAsAccruedInterest
17588 usd
hlyk Warrant Liability Incurred In Connection With Collection Of Contingent Sale Consideration Receivable
WarrantLiabilityIncurredInConnectionWithCollectionOfContingentSaleConsiderationReceivable
10820 usd
hlyk Net Carrying Value Of Equity Liabilitiesassets Written Off
NetCarryingValueOfEquityLiabilitiesassetsWrittenOff
12147 usd
hlyk Proceeds From Sale Of Common Stock Under Standby Equity Purchase Agreement Applied To Note
ProceedsFromSaleOfCommonStockUnderStandbyEquityPurchaseAgreementAppliedToNote
18765 usd
hlyk Fair Value Of Shares Issued To Pay Vendor Accounts Payable Balance
FairValueOfSharesIssuedToPayVendorAccountsPayableBalance
48881 usd
hlyk Fair Value Of Shares Issuable For Cost Of Equity
FairValueOfSharesIssuableForCostOfEquity
29134 usd
CY2014Q3 hlyk Number Of Authorized Shares
NumberOfAuthorizedShares
250000000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets; cash flow and fair value assumptions associated with measurements of contingent sale consideration receivable, contingent acquisition consideration payable, and impairment of intangible assets; valuation of inventory; collection of accounts receivable; the valuation and recognition of stock-based compensation expense; valuation allowance for deferred tax assets; and borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.</p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 hlyk Cash Balances In Excess Of Fdic Insured Limit
CashBalancesInExcessOfFDICInsuredLimit
0 usd
CY2023Q4 hlyk Cash Balances In Excess Of Fdic Insured Limit
CashBalancesInExcessOfFDICInsuredLimit
0 usd
hlyk Percentage Of Customers Accounts Receivable Billings
PercentageOfCustomersAccountsReceivableBillings
0.59 pure
CY2024Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
43612 usd
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
34481 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
25557 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20861 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentrations of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 pure
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14958 usd
hlyk Working Capital Deficit
WorkingCapitalDeficit
1982113 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46934409 usd
us-gaap Net Income Loss
NetIncomeLoss
-4901273 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2750520 usd
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
3010000 usd
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
894146 usd
CY2022Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
30000000 shares
CY2024Q3 us-gaap Cash Including Discontinued Operations
CashIncludingDiscontinuedOperations
750000 usd
CY2023Q1 hlyk Stub Period Reimbursements
StubPeriodReimbursements
31381 usd
CY2023Q4 us-gaap Other Receivables Gross Current
OtherReceivablesGrossCurrent
1873993 usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
500000 usd
hlyk Aggregate Merger Consideration Percentage
AggregateMergerConsiderationPercentage
0.01 pure
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
23646 usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
13554 usd
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
95941 usd
CY2023Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-13554 usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-72295 usd
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-13554 usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-72295 usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-84946 usd
hlyk Cash Consideration Paid At Signing
CashConsiderationPaidAtSigning
750000 usd
hlyk Incremental Cash Consideration
IncrementalCashConsideration
1311567 usd
hlyk Initial Public Offering Share Consideration
InitialPublicOfferingShareConsideration
1463517 usd
hlyk Two Zero Two Two Mssp Consideration
TwoZeroTwoTwoMSSPConsideration
312987 usd
hlyk Physician Advance Consideration
PhysicianAdvanceConsideration
199645 usd
hlyk Stub Period Reimbursement
StubPeriodReimbursement
31381 usd
hlyk Fair Value Of Contingent Consideration Receivable
FairValueOfContingentConsiderationReceivable
3319097 usd
hlyk L Fair Values Of Consideration Received And Receivable
lFairValuesOfConsiderationReceivedAndReceivable
4069097 usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets
1500 usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Intangible Assets
DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
1073000 usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Goodwill1
DisposalGroupIncludingDiscontinuedOperationGoodwill1
381856 usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Other Liabilities
DisposalGroupIncludingDiscontinuedOperationOtherLiabilities
20278 usd
CY2024Q3 hlyk Disposal Group Contingent Acquisition Consideration
DisposalGroupContingentAcquisitionConsideration
185024 usd
CY2024Q3 hlyk Discontinued Operation Amounts Of Net Book Value Of Assets And Liabilities Sold
DiscontinuedOperationAmountsOfNetBookValueOfAssetsAndLiabilitiesSold
1251054 usd
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
-2674069 usd
hlyk Fair Value Of Consideration Received And Receivable
FairValueOfConsiderationReceivedAndReceivable
-4069097 usd
hlyk Net Book Value Of Assets And Liabilities Sold
NetBookValueOfAssetsAndLiabilitiesSold
-1251054 usd
hlyk Fair Value Of Indemnification Clause
FairValueOfIndemnificationClause
-143974 usd
hlyk Gain From Disposal Of Discontinued Operations
GainFromDisposalOfDiscontinuedOperations
2674069 usd
CY2023Q3 hlyk Percentage Of Cash Consideration
PercentageOfCashConsideration
1 pure
CY2024Q4 hlyk Received Gross Proceeds
ReceivedGrossProceeds
500000 usd
CY2024Q4 us-gaap Proceeds From Commissions Received
ProceedsFromCommissionsReceived
325000 usd
CY2023Q3 hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
1075857 usd
hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
1090857 usd
CY2024Q3 hlyk Physician Advance Consideration Value
PhysicianAdvanceConsiderationValue
199645 usd
CY2023Q4 hlyk Physician Advance Consideration Value
PhysicianAdvanceConsiderationValue
199645 usd
CY2024Q3 hlyk Initial Public Offering Share Consideration Value
InitialPublicOfferingShareConsiderationValue
1463518 usd
CY2023Q4 hlyk Initial Public Offering Share Consideration Value
InitialPublicOfferingShareConsiderationValue
1463518 usd
CY2024Q3 hlyk Contingent Sales Consideration Receivable Long Term Portion
ContingentSalesConsiderationReceivableLongTermPortion
1663163 usd
CY2023Q4 hlyk Contingent Sales Consideration Receivable Long Term Portion
ContingentSalesConsiderationReceivableLongTermPortion
1663163 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
7377 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
11209 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
29158 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
38391 usd
CY2024Q3 us-gaap Prepaid Rent
PrepaidRent
50047 usd
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
50547 usd
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
5445 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
5110 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
92027 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
105257 usd
CY2024Q3 hlyk Deferred Equity Compensation And Deposit
DeferredEquityCompensationAndDeposit
50047 usd
CY2023Q4 hlyk Deferred Equity Compensation And Deposit
DeferredEquityCompensationAndDeposit
50047 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
41980 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
55210 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
811415 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
811817 usd
CY2024Q3 us-gaap Property Plant And Equipment Other Accumulated Depreciation
PropertyPlantAndEquipmentOtherAccumulatedDepreciation
606403 usd
CY2023Q4 us-gaap Property Plant And Equipment Other Accumulated Depreciation
PropertyPlantAndEquipmentOtherAccumulatedDepreciation
521062 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
205012 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
290755 usd
CY2024Q3 us-gaap Depreciation
Depreciation
27666 usd
CY2023Q3 us-gaap Depreciation
Depreciation
30352 usd
us-gaap Depreciation
Depreciation
86666 usd
us-gaap Depreciation
Depreciation
92642 usd
CY2024Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1675 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1675 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1142538 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
0 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
258690 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
883848 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
55077 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
57040 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167848 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
171120 usd
CY2023Q3 hlyk Revenue Decline Percentage
RevenueDeclinePercentage
0.65 pure
CY2024Q2 hlyk Revenue Decline Percentage
RevenueDeclinePercentage
0.35 pure
us-gaap Asset Impairment Charges
AssetImpairmentCharges
716000 usd
CY2024Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
CY2022Q2 us-gaap Goodwill
Goodwill
319958 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
319958 usd
CY2023Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.2368 pure
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36319 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
37466 usd
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
1148 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
678622 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
935812 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
329322 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
326033 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
350951 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
613386 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
680273 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
939419 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
126211 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
123572 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
385610 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
345759 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
133639 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
452672 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
329364 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
989 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
916664 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
236391 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
680273 usd
CY2024Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
470715 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
251479 usd
CY2024Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
51518 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
110103 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
57410 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91238 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
98119 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
57074 usd
CY2024Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
25000 usd
CY2023Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
100000 usd
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
2189 usd
CY2024Q3 hlyk Product Return Allowance Current
ProductReturnAllowanceCurrent
2191 usd
CY2023Q4 hlyk Product Return Allowance Current
ProductReturnAllowanceCurrent
2095 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
704953 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
614178 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
212793 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
271774 usd
CY2023Q3 us-gaap Debt Instrument Issued Principal
DebtInstrumentIssuedPrincipal
330000 usd
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due
FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue
0.05 pure
CY2023Q4 us-gaap Investment Interest Rate
InvestmentInterestRate
0 pure
CY2023Q4 hlyk Repaid Cash Premium Percentage
RepaidCashPremiumPercentage
0.02 pure
CY2023Q4 us-gaap Repayments Of Short Term Debt Maturing In Three Months Or Less
RepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
343200 usd
CY2023Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
308500 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
500000 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.15
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
25311 usd
CY2023Q3 us-gaap Other Notes Payable
OtherNotesPayable
343200 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
56739 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10000 usd
CY2023Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10000 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
93500 usd
CY2023Q3 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
85000 usd
CY2023Q3 us-gaap Longterm Debt Percentage Bearing Fixed Interest Amount
LongtermDebtPercentageBearingFixedInterestAmount
8500 usd
CY2023Q3 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.10 pure
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
850000 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.06
CY2023Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
31714 usd
CY2023Q3 us-gaap Other Notes Payable
OtherNotesPayable
93500 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
30672 usd
CY2024Q1 us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
0.0573
CY2024Q1 hlyk Warrants To Purchase Shares
WarrantsToPurchaseShares
6660000 shares
CY2024Q2 hlyk Warrants To Purchase Shares
WarrantsToPurchaseShares
393750 shares
CY2024Q3 us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
4130 usd
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
4130 usd
us-gaap Proceeds From Secured Notes Payable
ProceedsFromSecuredNotesPayable
855000 usd
us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
0.0486
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
271256 usd
CY2024Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
35654 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
35654 usd
us-gaap Debt Instrument Increase Decrease For Period Net
DebtInstrumentIncreaseDecreaseForPeriodNet
449365 usd
CY2023 us-gaap Debt Instrument Increase Decrease For Period Net
DebtInstrumentIncreaseDecreaseForPeriodNet
0 usd
CY2023 us-gaap Debt Instrument Increase Decrease For Period Net
DebtInstrumentIncreaseDecreaseForPeriodNet
0 usd
CY2024Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
300600 usd
CY2023Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
300600 usd
us-gaap Interest Income Other
InterestIncomeOther
19737 usd
us-gaap Interest Income Other
InterestIncomeOther
21530 usd
us-gaap Principal Transactions Revenue
PrincipalTransactionsRevenue
450000 usd
CY2023 us-gaap Principal Transactions Revenue
PrincipalTransactionsRevenue
450000 usd
CY2023Q4 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
125000 usd
CY2023Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
0 usd
CY2023Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
0 usd
CY2022Q3 hlyk Aggregate Daily Volume Percentage
AggregateDailyVolumePercentage
0.30 pure
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.96 pure
CY2022Q3 us-gaap Derivative Underlying Investment Shares
DerivativeUnderlyingInvestmentShares
30000000 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.17
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
438596 shares
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
406803 shares
hlyk Stock Issued During Period Sales Of Common Stock Persuant Standly By Equity Purchase Agreement
StockIssuedDuringPeriodSalesOfCommonStockPersuantStandlyByEquityPurchaseAgreement
29134 usd
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
7416667 shares
us-gaap Proceeds From Loans
ProceedsFromLoans
475000 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3062500 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.2
us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
0.0569
us-gaap Other Expenses
OtherExpenses
15400 usd
hlyk Common Stock Issuables Value
CommonStockIssuablesValue
147509 usd
hlyk Common Stock Issuables Shares
CommonStockIssuablesShares
2649203 shares
CY2023 hlyk Common Stock Issuables Value
CommonStockIssuablesValue
281682 usd
CY2023 hlyk Common Stock Issuables Shares
CommonStockIssuablesShares
2764352 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
29607667 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
12469698 shares
CY2024Q3 us-gaap Derivative Net Liability Position Aggregate Fair Value
DerivativeNetLiabilityPositionAggregateFairValue
1037535 usd
CY2023Q3 us-gaap Derivative Net Liability Position Aggregate Fair Value
DerivativeNetLiabilityPositionAggregateFairValue
584572 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5093738 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.16
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5222982 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4804974 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
93750 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3651795 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
623000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.18
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6246917 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.07
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4693732 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.16
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4884417 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.07
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3054315 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
Binomial Lattice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
Binomial Lattice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0348 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4503 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
hlyk Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.30 pure
hlyk Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.30 pure
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
653 usd
us-gaap Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1
NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1
P0Y10M24D
CY2024Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0
CY2023Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.05
CY2024Q3 us-gaap Additional Collateral Aggregate Fair Value
AdditionalCollateralAggregateFairValue
60588 usd
CY2023Q3 us-gaap Additional Collateral Aggregate Fair Value
AdditionalCollateralAggregateFairValue
72756 usd
CY2024Q3 us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
0 usd
CY2023Q3 us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
0 usd
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
0 usd
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
10353 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
133639 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
452672 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
329364 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
989 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
916664 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
236391 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
680273 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 pure
CY2024Q3 us-gaap Revenues
Revenues
590124 usd
CY2024Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
449759 usd
CY2024Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
349467 usd
CY2024Q3 hlyk Cost Of Product Revenue
CostOfProductRevenue
31674 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
631828 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
82743 usd
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
716000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2261471 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1671347 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2580 usd
CY2024Q3 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
65344 usd
CY2024Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
322141 usd
CY2024Q3 hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
1478 usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
49033 usd
us-gaap Revenues
Revenues
2389434 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
1546806 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1221272 usd
hlyk Cost Of Product Revenue
CostOfProductRevenue
86976 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2492740 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
254514 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
716000 usd
us-gaap Operating Expenses
OperatingExpenses
6318308 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3928874 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-167647 usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
93244 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
801762 usd
hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
2189 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
98423 usd
CY2024Q3 us-gaap Assets
Assets
2758158 usd
CY2023Q4 us-gaap Assets
Assets
4280140 usd
CY2023Q3 us-gaap Revenues
Revenues
1332515 usd
CY2023Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
772416 usd
CY2023Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
529067 usd
CY2023Q3 hlyk Cost Of Product Revenue
CostOfProductRevenue
40820 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
767705 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
87392 usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
319958 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2517358 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1184843 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
92641 usd
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
132155 usd
CY2023Q3 hlyk Gain From Realization Of Contingent Sale Of Consideration Receivable
GainFromRealizationOfContingentSaleOfConsiderationReceivable
-1075857 usd
CY2023Q3 hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
4819 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
17689 usd
us-gaap Revenues
Revenues
4791165 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
2635065 usd
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1799530 usd
hlyk Cost Of Product Revenue
CostOfProductRevenue
107277 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2705142 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
263762 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
319958 usd
us-gaap Operating Expenses
OperatingExpenses
7830734 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3039569 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-88932 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
92641 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
324204 usd
hlyk Gain From Realization Of Contingent Sale Of Consideration Receivable
GainFromRealizationOfContingentSaleOfConsiderationReceivable
-1090857 usd
hlyk Gain Loss On Change In Fair Value Of Contingent Acquisition Consideration
GainLossOnChangeInFairValueOfContingentAcquisitionConsideration
9183 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
68194 usd
CY2023Q3 us-gaap Assets
Assets
5689324 usd
CY2024Q3 hlyk Changes In Fair Value Of Debt
ChangesInFairValueOfDebt
65344 usd
hlyk Changes In Fair Value Of Debt
ChangesInFairValueOfDebt
93244 usd
CY2024Q3 hlyk Contingent Acquisition Consideration Payable
ContingentAcquisitionConsiderationPayable
1478 usd
CY2023Q3 hlyk Contingent Acquisition Consideration Payable
ContingentAcquisitionConsiderationPayable
4819 usd
hlyk Contingent Acquisition Consideration Payable
ContingentAcquisitionConsiderationPayable
2189 usd
hlyk Contingent Acquisition Consideration Payable
ContingentAcquisitionConsiderationPayable
9183 usd
CY2024Q3 hlyk Financial Liabilities At Fair Value Disclosure
FinancialLiabilitiesAtFairValueDisclosure
66822 usd
CY2023Q3 hlyk Financial Liabilities At Fair Value Disclosure
FinancialLiabilitiesAtFairValueDisclosure
4819 usd
hlyk Financial Liabilities At Fair Value Disclosure
FinancialLiabilitiesAtFairValueDisclosure
95433 usd
hlyk Financial Liabilities At Fair Value Disclosure
FinancialLiabilitiesAtFairValueDisclosure
9183 usd
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
usd
CY2024Q3 hlyk Contingent Sale Consideration Receivable Long Term Portion
ContingentSaleConsiderationReceivableLongTermPortion
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
usd
CY2024Q3 hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
usd
hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2024Q3 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
usd
us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
usd
CY2024Q3 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
usd
CY2023Q3 us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
usd
us-gaap Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation
DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
usd
CY2024Q3 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
usd
us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
usd
hlyk Gain From Disposal Of Discontinued Operations
GainFromDisposalOfDiscontinuedOperations
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
usd
hlyk Gain From Expiration Of Liability Classified Equity Instruments
GainFromExpirationOfLiabilityClassifiedEquityInstruments
usd
us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
usd
hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
hlyk Proceeds From Sale Of Discontinued Operations
ProceedsFromSaleOfDiscontinuedOperations
usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
usd
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
hlyk Extinguishment Of Operating Lease Right Of Use Asset And Lease Liability
ExtinguishmentOfOperatingLeaseRightOfUseAssetAndLeaseLiability
usd
hlyk Common Stock To Be Issued Now Issued
CommonStockToBeIssuedNowIssued
usd
hlyk Fair Value Of Options Issued In Satisfaction Of Common Stock Issuable
FairValueOfOptionsIssuedInSatisfactionOfCommonStockIssuable
usd
hlyk Fair Value Of Warrants Allocated To Proceeds Of Third Party Notes Payable
FairValueOfWarrantsAllocatedToProceedsOfThirdPartyNotesPayable
usd
hlyk Fair Value Of Beneficial Conversion Feature Allocated To Proceeds Of Related Party Notes Payable
FairValueOfBeneficialConversionFeatureAllocatedToProceedsOfRelatedPartyNotesPayable
usd
hlyk Incremental Fair Value Of Convertible Note Payable To Related Party Resulting From Refinancing
IncrementalFairValueOfConvertibleNotePayableToRelatedPartyResultingFromRefinancing
usd
hlyk Note Payable To Related Party Balance Classified As Accrued Interest
NotePayableToRelatedPartyBalanceClassifiedAsAccruedInterest
usd
hlyk Warrant Liability Incurred In Connection With Collection Of Contingent Sale Consideration Receivable
WarrantLiabilityIncurredInConnectionWithCollectionOfContingentSaleConsiderationReceivable
usd
hlyk Net Carrying Value Of Equity Liabilitiesassets Written Off
NetCarryingValueOfEquityLiabilitiesassetsWrittenOff
usd
hlyk Proceeds From Sale Of Common Stock Under Standby Equity Purchase Agreement Applied To Note
ProceedsFromSaleOfCommonStockUnderStandbyEquityPurchaseAgreementAppliedToNote
usd
hlyk Fair Value Of Shares Issued To Pay Vendor Accounts Payable Balance
FairValueOfSharesIssuedToPayVendorAccountsPayableBalance
usd
hlyk Fair Value Of Shares Issuable For Cost Of Equity
FairValueOfSharesIssuableForCostOfEquity
usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
usd
CY2023Q3 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
usd
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
usd
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
usd
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
usd
CY2024Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
usd
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
usd
CY2024Q3 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
CY2023Q3 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
usd
CY2024Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2024Q3 hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
usd
hlyk Gain From Realization Of Contingent Sale Consideration Receivable
GainFromRealizationOfContingentSaleConsiderationReceivable
usd
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
CY2023Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
usd
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
usd
CY2024Q3 us-gaap Warrants And Rights Outstanding Measurement Input Extensible List
WarrantsAndRightsOutstandingMeasurementInputExtensibleList
http://www.healthlynked.com/20240930#MeasurementInputPricingModelUtilizedMember
CY2023Q3 us-gaap Warrants And Rights Outstanding Measurement Input Extensible List
WarrantsAndRightsOutstandingMeasurementInputExtensibleList
http://www.healthlynked.com/20240930#MeasurementInputPricingModelUtilizedMember
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q3 hlyk Changes In Fair Value Of Debt
ChangesInFairValueOfDebt
usd
hlyk Changes In Fair Value Of Debt
ChangesInFairValueOfDebt
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001680139
dei No Trading Symbol Flag
NoTradingSymbolFlag
true

Files In Submission

Name View Source Status
0001213900-24-098383-index-headers.html Edgar Link pending
0001213900-24-098383-index.html Edgar Link pending
0001213900-24-098383.txt Edgar Link pending
0001213900-24-098383-xbrl.zip Edgar Link pending
ea0219990-10q_health.htm Edgar Link pending
ea021999001ex31-1_health.htm Edgar Link pending
ea021999001ex31-2_health.htm Edgar Link pending
ea021999001ex32-1_health.htm Edgar Link pending
ea021999001ex32-2_health.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hlyk-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
hlyk-20240930_cal.xml Edgar Link unprocessable
hlyk-20240930_def.xml Edgar Link unprocessable
hlyk-20240930_lab.xml Edgar Link unprocessable
hlyk-20240930_pre.xml Edgar Link unprocessable
ea0219990-10q_health_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable